- Home
- AIFF vs PTN Comparison
AIFF vs PTN Comparison
Compare AIFF & PTN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIFF
- PTN
- Stock Information
- Founded
- AIFF 2006
- PTN 1986
- Country
- AIFF Canada
- PTN United States
- Employees
- AIFF N/A
- PTN N/A
- Industry
- AIFF
- PTN Biotechnology: Pharmaceutical Preparations
- Sector
- AIFF
- PTN Health Care
- Exchange
- AIFF NYSE
- PTN Nasdaq
- Market Cap
- AIFF 26.6M
- PTN 25.4M
- IPO Year
- AIFF N/A
- PTN 1993
- Fundamental
- Price
- AIFF $2.33
- PTN $0.98
- Analyst Decision
- AIFF
- PTN Strong Buy
- Analyst Count
- AIFF 0
- PTN 1
- Target Price
- AIFF N/A
- PTN $17.00
- AVG Volume (30 Days)
- AIFF 59.4K
- PTN 573.0K
- Earning Date
- AIFF 11-14-2024
- PTN 02-13-2025
- Dividend Yield
- AIFF N/A
- PTN N/A
- EPS Growth
- AIFF N/A
- PTN N/A
- EPS
- AIFF N/A
- PTN N/A
- Revenue
- AIFF $74,000.00
- PTN $2,384,113.00
- Revenue This Year
- AIFF N/A
- PTN N/A
- Revenue Next Year
- AIFF N/A
- PTN N/A
- P/E Ratio
- AIFF N/A
- PTN N/A
- Revenue Growth
- AIFF N/A
- PTN N/A
- 52 Week Low
- AIFF $2.32
- PTN $0.68
- 52 Week High
- AIFF $15.90
- PTN $5.65
- Technical
- Relative Strength Index (RSI)
- AIFF 32.31
- PTN 51.82
- Support Level
- AIFF $2.89
- PTN $0.82
- Resistance Level
- AIFF $3.25
- PTN $0.99
- Average True Range (ATR)
- AIFF 0.28
- PTN 0.12
- MACD
- AIFF -0.07
- PTN -0.00
- Stochastic Oscillator
- AIFF 0.93
- PTN 55.15
About AIFF FIREFLY NEUROSCIENCE INC
Firefly Neuroscience Inc is an AI company developing innovative neuroscientific solutions that improve outcomes for patients with mental illnesses and cognitive disorders. It is focused on the commercialization of its Brain Network Analytics (BNA) software platform (the "BNA Platform")and the discovery and clinical development of biomarkers that support better outcomes for people suffering from mental illnesses and cognitive disorders.
About PTN Palatin Technologies Inc.
Palatin Technologies Inc is a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system. The product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with significant unmet medical need and commercial potential.